Creating a unified digital ecosystem for clinical trials (CT) can turn data transparency into a key competitiveness factor for the Eurasian Economic Union. The proposal to establish a common registry of clinical trials, research centers, and inspections was put forward by Maria Leer, Quality Director for Clinical Trials at AstraZeneca (Russia and Eurasia), at the 17th International Eurasian Pharmaceutical Forum.
According to the expert, current data fragmentation in EAEU countries limits industry development. Existing national registries often contain minimal information and do not provide a complete picture of the quality of centers or the design of ongoing trials. This creates uncertainty for sponsors: in countries with low transparency, up to 40–60% of projects face difficulties in patient recruitment, leading to average delays of 8–12 months and a 30–50% increase in development costs.
Transitioning to open data exchange will change the situation. The formation of unified registries will create a clear environment where participants can clearly understand regulator requirements and plan programs more effectively.
“In the long term, transparency can become a competitive advantage for the entire EAEU region, facilitating the attraction of international clinical trials, expanding patient access to innovative treatments, and developing the local expert base”.
— Maria Leer, Quality Director for Clinical Trials, AstraZeneca, Russia and Eurasia
Global experience confirms the effectiveness of this approach. Mandatory data disclosure systems are already operating in the USA, the European Union, and China, where the vector is shifting from simple publication of results to proactive public information. For the EAEU, the implementation of a full-fledged Clinical Trial Transparency system will ensure increased trust in national systems for regulators, and reduce operational and reputational risks for sponsors.
